← Medeze Group PCL overview

Medeze Group PCL vs Encompass Health: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Medeze Group PCL (MEDEZE.BK)

Q3 2026
▲4

Medeze advances ATMP hub role with FDA license, partnerships, and expansion

  • Thai FDA drug manufacturing license and ATMP Sandbox Medeze obtained a modern drug manufacturing license from the Thai FDA and became the first in Thailand to meet Cell Bank standards, joining the ATMP Regulatory Sandbox. This regulatory progress strengthens its leadership and opens doors to advanced therapies, supporting future revenue growth.

    This is a key regulatory milestone that directly enhances Medeze's competitive position and future business prospects.

  • Partnership with Bangkok Hospital Udon Medeze signed an MOU with Bangkok Hospital Udon to offer stem cell storage, immune testing, and anti-aging services. This expands its customer base and demand for its services, likely boosting revenue and market presence.

    This partnership directly increases demand for Medeze's services and expands its reach.

  • Second-half recovery and expansion plans Medeze expects Q3 2026 results to recover, with GMP approval expected by Q4 2026, clinical trials for knee osteoarthritis and skin rejuvenation starting soon, and Philippine expansion via franchise. These initiatives signal growth and product pipeline progress.

    This provides concrete updates on operational recovery and future growth drivers.

  • GMDP certification for cell therapy production Medeze received GMDP PIC/S certification from the Thai FDA, allowing production for Phase 1-2 human trials of mesenchymal stem cells. This regulatory approval validates its manufacturing quality and supports future commercial cell therapies.

    This certification is a critical step toward commercializing advanced therapies, enhancing long-term growth potential.

August 2026
▲4

Medeze advances ATMP hub role with FDA license, partnerships, and expansion

  • Thai FDA drug manufacturing license and ATMP Sandbox Medeze obtained a modern drug manufacturing license from the Thai FDA and became the first in Thailand to meet Cell Bank standards, joining the ATMP Regulatory Sandbox. This regulatory progress strengthens its leadership and opens doors to advanced therapies, supporting future revenue growth.

    This is a key regulatory milestone that directly enhances Medeze's competitive position and future business prospects.

  • Partnership with Bangkok Hospital Udon Medeze signed an MOU with Bangkok Hospital Udon to offer stem cell storage, immune testing, and anti-aging services. This expands its customer base and demand for its services, likely boosting revenue and market presence.

    This partnership directly increases demand for Medeze's services and expands its reach.

  • Second-half recovery and expansion plans Medeze expects Q3 2026 results to recover, with GMP approval expected by Q4 2026, clinical trials for knee osteoarthritis and skin rejuvenation starting soon, and Philippine expansion via franchise. These initiatives signal growth and product pipeline progress.

    This provides concrete updates on operational recovery and future growth drivers.

  • GMDP certification for cell therapy production Medeze received GMDP PIC/S certification from the Thai FDA, allowing production for Phase 1-2 human trials of mesenchymal stem cells. This regulatory approval validates its manufacturing quality and supports future commercial cell therapies.

    This certification is a critical step toward commercializing advanced therapies, enhancing long-term growth potential.

Latest
▲4

Medeze advances ATMP hub role with FDA license, partnerships, and expansion

  • Thai FDA drug manufacturing license and ATMP Sandbox Medeze obtained a modern drug manufacturing license from the Thai FDA and became the first in Thailand to meet Cell Bank standards, joining the ATMP Regulatory Sandbox. This regulatory progress strengthens its leadership and opens doors to advanced therapies, supporting future revenue growth.

    This is a key regulatory milestone that directly enhances Medeze's competitive position and future business prospects.

  • Partnership with Bangkok Hospital Udon Medeze signed an MOU with Bangkok Hospital Udon to offer stem cell storage, immune testing, and anti-aging services. This expands its customer base and demand for its services, likely boosting revenue and market presence.

    This partnership directly increases demand for Medeze's services and expands its reach.

  • Second-half recovery and expansion plans Medeze expects Q3 2026 results to recover, with GMP approval expected by Q4 2026, clinical trials for knee osteoarthritis and skin rejuvenation starting soon, and Philippine expansion via franchise. These initiatives signal growth and product pipeline progress.

    This provides concrete updates on operational recovery and future growth drivers.

  • GMDP certification for cell therapy production Medeze received GMDP PIC/S certification from the Thai FDA, allowing production for Phase 1-2 human trials of mesenchymal stem cells. This regulatory approval validates its manufacturing quality and supports future commercial cell therapies.

    This certification is a critical step toward commercializing advanced therapies, enhancing long-term growth potential.

Encompass Health Corp (EHC)

Q3 2026
▲3

EHC beats and raises again, adds capacity as Medicare rates rise

  • Q2 beat and second guidance raise Encompass Health beat second-quarter expectations, with revenue up 9.6% to $1.6 billion and adjusted EPS of $1.55 ahead of estimates, then raised full-year revenue and profit guidance for the second time this year. Higher expected earnings support a higher stock price.

    The earnings beat and raised outlook are the core new fundamental driver of the stock.

  • Medicare rehab rate increase finalized Federal regulators finalized a rule lifting Medicare payments for inpatient rehabilitation by about 2.3% starting in October. Medicare is a major payer for EHC, so higher set rates lift revenue per patient and helped management raise its outlook.

    A regulatory rate change directly raises EHC's reimbursement and future revenue.

  • Capacity expansion, including first small-format hospital EHC announced its first small-format inpatient rehabilitation hospital in Conroe, Texas, plus a 60-bed replacement hospital in The Woodlands. Adding beds and a new lower-cost model extends its reach into growing communities and supports future growth.

    New hospital projects show how EHC plans to grow revenue beyond current guidance.

  • Insider share sales and debt risk temper the good news The CFO, CEO and general counsel sold shares after the stock hit near a 52-week high, which can unsettle investors. EHC also carries net debt of 41.4% of capital, above the industry average, and shares slipped 1.8% after earnings.

    This is the real counterweight: insider selling and leverage could hold the stock back.

August 2026
▲3

EHC beats and raises again, adds capacity as Medicare rates rise

  • Q2 beat and second guidance raise Encompass Health beat second-quarter expectations, with revenue up 9.6% to $1.6 billion and adjusted EPS of $1.55 ahead of estimates, then raised full-year revenue and profit guidance for the second time this year. Higher expected earnings support a higher stock price.

    The earnings beat and raised outlook are the core new fundamental driver of the stock.

  • Medicare rehab rate increase finalized Federal regulators finalized a rule lifting Medicare payments for inpatient rehabilitation by about 2.3% starting in October. Medicare is a major payer for EHC, so higher set rates lift revenue per patient and helped management raise its outlook.

    A regulatory rate change directly raises EHC's reimbursement and future revenue.

  • Capacity expansion, including first small-format hospital EHC announced its first small-format inpatient rehabilitation hospital in Conroe, Texas, plus a 60-bed replacement hospital in The Woodlands. Adding beds and a new lower-cost model extends its reach into growing communities and supports future growth.

    New hospital projects show how EHC plans to grow revenue beyond current guidance.

  • Insider share sales and debt risk temper the good news The CFO, CEO and general counsel sold shares after the stock hit near a 52-week high, which can unsettle investors. EHC also carries net debt of 41.4% of capital, above the industry average, and shares slipped 1.8% after earnings.

    This is the real counterweight: insider selling and leverage could hold the stock back.

Latest
▲3

EHC beats and raises again, adds capacity as Medicare rates rise

  • Q2 beat and second guidance raise Encompass Health beat second-quarter expectations, with revenue up 9.6% to $1.6 billion and adjusted EPS of $1.55 ahead of estimates, then raised full-year revenue and profit guidance for the second time this year. Higher expected earnings support a higher stock price.

    The earnings beat and raised outlook are the core new fundamental driver of the stock.

  • Medicare rehab rate increase finalized Federal regulators finalized a rule lifting Medicare payments for inpatient rehabilitation by about 2.3% starting in October. Medicare is a major payer for EHC, so higher set rates lift revenue per patient and helped management raise its outlook.

    A regulatory rate change directly raises EHC's reimbursement and future revenue.

  • Capacity expansion, including first small-format hospital EHC announced its first small-format inpatient rehabilitation hospital in Conroe, Texas, plus a 60-bed replacement hospital in The Woodlands. Adding beds and a new lower-cost model extends its reach into growing communities and supports future growth.

    New hospital projects show how EHC plans to grow revenue beyond current guidance.

  • Insider share sales and debt risk temper the good news The CFO, CEO and general counsel sold shares after the stock hit near a 52-week high, which can unsettle investors. EHC also carries net debt of 41.4% of capital, above the industry average, and shares slipped 1.8% after earnings.

    This is the real counterweight: insider selling and leverage could hold the stock back.